Sankyo to Manufacture, Distribute Olmetic Antihypertensive Drug in China.Tokyo, Japan, Aug 4, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Shanghai Sankyo Pharmaceuticals Co., Ltd., the Chinese subsidiary of Sankyo Co., Ltd. of the Daiichi Sankyo Company, will start selling Olmetec - generic name generic name n. 1. The official nonproprietary name of a drug, under which it is licensed and identified by the manufacturer. 2. : olmesartan medoxomil olmesartan medoxomil Benicar, Olmetec (UK) Pharmacologic class: Angiotensin II type 1-receptor antagonist Therapeutic class: Antihypertensive Pregnancy risk category C (first trimester), D - an antihypertensive antihypertensive /an·ti·hy·per·ten·sive/ (-ten´siv) counteracting high blood pressure, or an agent that does this. an·ti·hy·per·ten·sive adj. Reducing high blood pressure. n. agent in July. Sankyo acquired manufacturing approval for the drug in April 2006. Olmetec tablets possess strong antihypertentive action compared with other ARBs (angiotensin II receptor blockers) has demonstrated string antihypertensive action in multiple double-blind comparative studies conducted in various countries. The drug was developed by Sankyo and launched in the US under the brand name Benicar in May 2002 and is now sold in more than 35 countries worldwide as Benicar or Olmetic. Daiichi Sankyo Group expects global sales of approximately 150 billion yen in fiscal year 2006. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. 
Daniel E. Pigg (Member): How can I get this drug at a reduced or no cost as I am on a low income 3/7/2009 8:14 AM
I have to take this drug to help control my blood pressure and living on a fixed incomne I have a hard time paying this high cost. Can you send me out papers to see if I can qualify for assisstance in acquiring this drug? |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion